Attralus Stock
HealthTechLooking to sell Attralus stock or options?
Attralus is engaged in creating immunotherapies and an imaging diagnostic platform aimed at treating multiple systemic amyloid diseases. The company's focus is on developing treatments to eliminate amyloid fibrils in patients suffering from systemic amyloid conditions such as light chain, transthyretin, and LECT2 amyloidosis. This enables the healthcare sector to provide more effective treatments for amyloidosis patients.
Samsara BioCapital, Logos Capital, Bristol-Myers Squibb, Surveyor Capital, LifeSci Venture Partners, Redmile Group, Vivo Capital, Janus Henderson Investors, Sarissa Capital Management, QB3, venBio, Biobrit, Citadel Enterprise Americas, Yarrow Capital, Alpha Wave Global.
Collective explained in 2 minutes
Learn how Collective's solutions enable you to manage your risk and maximize your wealth
Our available services for this company
Management Team
Board Members
Attralus’s stock FAQs
Attralus is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Attralus stock. Depending on Attralus’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Attralus stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Attralus stock in two ways. First, Attralus employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Attralus stock. Note that all transactions in Attralus shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Attralus stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Attralus stock. Typically, shares of private companies like Attralus are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Feb 2024, Attralus is reported to have closed an equity financing in which the investors valued the company at $429M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Attralus shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Attralus is not currently publicly traded, it does not have a ticker symbol.
Attralus has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Attralus is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Attralus shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
